DETRUSITOL RETARD 2mg price in UAE

Overview

Welcome to Dwaey, specifically on DETRUSITOL RETARD 2mg Capsules page.
This medicine contains an important and useful components, as it consists of Tolterodine l-tartrate.
DETRUSITOL RETARD 2mg is available in the market in concentration 2mg/Tablet and in the form of Capsules.

PHARMACIA & UPJOHN S.p.A. is the producer of DETRUSITOL RETARD 2mg and it is imported from ITALY, The most popular alternatives of DETRUSITOL RETARD 2mg are listed downward .

Mode Of Action

Tolterodine is a competitive muscarinic receptor antagonist with actions similar to atropine. It is used in the management of urge urinary incontinence, urgency and frequency.

Indication

Overactive bladder

Precaution

Bladder flow obstruction, GI obstructive disorders, renal or hepatic impairment, autonomic neuropathy, hiatus hernia, risk of decreased GI motility, patients at risk of QT interval prolongation (e.g. electrolyte disturbances, bradycardia, pre-exisiting cardiac disorder). Lactation: Unknown whether drug is distributed in breast milk; do not nurse

Side Effects

>10% Dry mouth (40%) 1-10% Blurred vision
Constipation
Dizziness
Drowsiness
Dyspepsia
Headache
Xerophthalmia

Contra indication

Severe ulcerative colitis, toxic megacolon, urinary retention, gastric retention, myasthenia gravis, uncontrolled narrow-angle glaucoma, pregnancy.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Increased risk of overdosage with potent CYP3A4 inhibitors e.g. macrolide antibiotics (erythromycin and clarithromycin), azole antifungals (e.g. ketoconazole and itraconazole), protease inhibitors, ciclosporin or vinblastine. Increased risk of torsade de pointes with drugs that prolong the QT interval (e.g. class Ia and class III antiarrhythmics). Increased risk of 'cholinergic neurogenic hypersensitivity' with centrally acting anticholinesterases (e.g. donepezil, rivastigmine). Increased risk of antimuscarinic side effects with antimuscarinic drugs.